BenevolentAI gets late-stage compounds from Janssen
Janssen Pharmaceutica NV licensed artificial intelligence firm BenevolentAI exclusive global rights to develop, manufacture, and commercialize a series of clinical-stage small-molecule drug candidates and related patents for all indications.
- Artificial Intelligence
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com